Novavax (NVAX) Research & Development (2010 - 2026)

Novavax's Research & Development history runs 17 years deep, the most recent figure standing at $95.5 million for Q1 2026.

• In Q1 2026, Research & Development rose 7.35% year-over-year to $95.5 million; the TTM figure through Mar 2026 stood at $348.9 million (down 9.96% YoY), while the FY2025 annual figure was $342.3 million, down 12.49% from the prior year.
• Research & Development for Q1 2026 stood at $95.5 million, up from $75.9 million in the prior quarter.
• The five-year high for Research & Development was $383.5 million in Q1 2022, with the low at $75.9 million in Q4 2025.
• The 5-year median for Research & Development is $106.2 million (2023), against an average of $164.8 million.
• The sharpest annual moves came in 2022 and 2025: Research & Development slumped 73.22% in 2022, then increased 12.75% in 2025.
• Novavax's Research & Development stood at $257.8 million in 2022, then slumped by 36.13% to $164.7 million in 2023, then slumped by 36.62% to $104.4 million in 2024, then retreated by 27.31% to $75.9 million in 2025, then advanced by 25.83% to $95.5 million in 2026.
• Business Quant data shows NVAX's Research & Development at $95.5 million in Q1 2026, $75.9 million in Q4 2025, and $98.3 million in Q3 2025.